TABLE 2.
Descriptive statistics of baseline categorical and continuous covariates for subjects who received inebilizumab treatment
| Study CP200 | Study 1102 | Study 1155 | Total | |
|---|---|---|---|---|
| n = 24 | n = 15 | n = 174 | n = 213 | |
| Sex, n (%) | ||||
| Male | 7 (29.2) | 6 (40) | 15 (8.6) | 28 (13.1) |
| Female | 17 (70.8) | 9 (60) | 159 (91.4) | 185 (86.9) |
| Race, n (%) | ||||
| White | 20 (83.3) | 13 (86.7) | 92 (52.9) | 125 (58.7) |
| Black | 3 (12.5) | 1 (6.7) | 15 (8.6) | 19 (8.9) |
| Asian | 0 | 0 | 39 (22.4) | 39 (18.3) |
| American Indian or Alaskan | 0 | 0 | 14 (8) | 14 (6.6) |
| Other | 1 (4.2) | 1 (6.7) | 14 (8) | 16 (7.5) |
| Anti‐drug antibody, n (%) | ||||
| Positive | 4 (16.7) | 0 | 17 (9.8) | 21 (9.9) |
| Age (y) | ||||
| Median | 48.5 | 44.0 | 43.0 | 44.0 |
| Range | 31.0–64.0 | 28.0–60.0 | 18.0–73.0 | 18.0–73.0 |
| Weight (kg) | ||||
| Mean (SD) | 73.6 (17.7) | 78.3 (21.9) | 68.3 (17.4) | 69.6 (17.9) |
| Median | 73.2 | 72.0 | 65.0 | 66.2 |
| Range | 41.1–114 | 54.0–122 | 38.0–148 | 38.0–148 |
| BMI (kg m −2 ) | ||||
| Mean (SD) | 26.3 (5.91) | 26.7 (5.90) | 25.2 (5.50) | 25.4 (5.57) |
| Median | 26.8 | 26.0 | 24.5 | 24.7 |
| Range | 15.7–37.9 | 19.8–38.6 | 15.6–52.8 | 15.6–52.8 |
| Total bilirubin (μmol L −1 ) | ||||
| Mean (SD) | 4.56 (2.35) | 9.13 (3.78) | 8.20 (5.23) | 7.86 (5.03) |
| Median | 4.28 | 8.00 | 7.00 | 7.00 |
| Range | 1.71–12.0 | 4.00–17.0 | 3.00–40.0 | 1.71–40.0 |
| Alkaline phosphatase (U L −1 ) | ||||
| Mean (SD) | 74.1 (20.6) | 79.7 (28.8) | 67.0 (25.5) | 68.7 (25.4) |
| Median | 73.5 | 90.0 | 63.0 | 66.0 |
| Range | 36.0–118 | 33.0–129 | 26.0–188 | 26.0–188 |
| Aspartate transaminase (U L −1 ) | ||||
| Mean (SD) | 22.1 (8.37) | 20.5 (6.74) | 22.4 (18.9) | 22.3 (17.4) |
| Median | 21.0 | 21.0 | 19.0 | 19.0 |
| Range | 9.00–53.0 | 12.0–33.0 | 7.00–164 | 7.00–164 |
| Creatinine clearance (mL min −1 ) | ||||
| Mean (SD) | 129 (55.1) | 126 (47.4) | 119 (39.7) | 121 (42.2) |
| Median | 122 | 108 | 110 | 110 |
| Range | 51.5–282 | 84.1–245 | 50.9–247 | 50.9–282 |
| Estimated glomerular filtration rate (mL min −1 1.73 m 2 ) | ||||
| Mean (SD) | 113 (50.7) | 96.1 (19.6) | 103 (26.5) | 103 (29.9) |
| Median | 107 | 93.1 | 97.0 | 96.6 |
| Range | 42.8–292 | 67.6–128 | 56.9–226 | 42.8–292 |
| CD20 (cells μL −1 ) | ||||
| Mean (SD) | 161 (143) | 187 (66.6) | 205 (129) | 198 (128) |
| Median | 108 | 182 | 183 | 174 |
| Range | 22.0–624 | 93.4–319 | 6.28–676 | 6.28–676 |
SD, standard deviation.